Biogen Inc. / Nightstar Therapeutics

X-Linked Retinitis Pigmentosa

200 US cases/yr · $500M IRD Gene Therapy Market Opportunity

Disease Overview

X-linked retinitis pigmentosa (XLRP) is caused by RPGR gene mutations and is the most severe form of RP, causing progressive photoreceptor loss. XLRP accounts for ~10-20% of all RP cases. Gene therapy to deliver RPGR aims to slow or halt progression.

Development Status

Biogen's NSR-RPGR (BIIB112) targets RPGR-mutated XLRP via AAV8 gene therapy. The program has shown some evidence of slowing disease progression. Competing programs include those from MeiraGTx/Janssen. The XLRP patient population is larger than choroideremia, improving commercial potential.

Choroideremia

50 US cases/yr · $100M Estimated Market Opportunity

Disease Overview

Choroideremia is a rare X-linked recessive retinal degeneration caused by CHM gene mutations affecting the REP-1 protein. It leads to progressive vision loss in males, typically starting in childhood. Gene therapy to deliver functional REP-1 is the primary therapeutic approach.

Gene Therapy Development

Biogen acquired Nightstar to access NSR-REP1 (timrepigene emparvovec), an AAV2 gene therapy for choroideremia. Phase III (STAR trial) results were mixed. The choroideremia gene therapy field faces challenges with small patient populations and variable disease progression making endpoints difficult.

X-linked retinitis pigmentosa (XLRP)

Disease Overview

X-linked retinitis pigmentosa (XLRP) is an inherited retinal degeneration caused by mutations in RPGR, leading to progressive rod-then-cone photoreceptor loss and blindness, primarily in males. It typically presents earlier and progresses faster than autosomal forms of RP.

Competitive Landscape

NSR-RPGR (now part of the Nightstar pipeline acquired) was entering Phase 2/3 in early 2019, competing in a crowded XLRP gene therapy field that included AGTC's AAV-RPGR (partnered with Biogen prior to the Nightstar deal — creating overlap), MeiraGTx/Janssen's botaretigene sparoparvovec (AAV-RPGR), and 4D Molecular Therapeutics' intravitreal approach. The Biogen-Nightstar transaction effectively consolidated two competing XLRP gene therapy programs under Biogen, given the existing AGTC partnership, raising portfolio-rationalization questions covered by Fierce Biotech. With Spark out of independent dealmaking after Roche's bid and J&J/MeiraGTx aligned, the deal sealed Biogen's IRD platform ambitions. The Nightstar XLRP program was ultimately discontinued post-acquisition alongside the choroideremia setback.

Choroideremia

Disease Overview

Choroideremia is a rare X-linked recessive retinal degeneration caused by loss-of-function mutations in the CHM gene encoding REP1. It predominantly affects males, beginning with night blindness in childhood and progressing to peripheral and central vision loss by mid-adulthood. No approved therapy existed at the time of the Biogen-Nightstar deal, leaving patients facing inevitable legal blindness.

Competitive Landscape

At deal time (March 2019), the inherited retinal disease (IRD) gene therapy field was rapidly emerging in the wake of Spark Therapeutics' Luxturna (voretigene neparvovec), the first FDA-approved gene therapy for an IRD (RPE65-related retinal dystrophy, December 2017). Spark itself was being acquired by Roche for $4.8B (announced February 2019), creating bidding pressure that SVB Leerink analyst Joseph Schwartz cited as motivation for Biogen 'pulling the trigger' on Nightstar. Direct choroideremia competitors included AGTC's AAV-CHM program and academic Oxford/MeiraGTx Phase 1/2 work; MeiraGTx had a J&J partnership covering multiple IRDs including XLRP (NSR-RPGR's indication). Nightstar's NSR-REP1 was the most clinically advanced choroideremia gene therapy, in Phase 3 STAR. The deal positioned Biogen to enter ophthalmology gene therapy beyond its core neurology franchise, leveraging AAV expertise from Spinraza follow-ons. Subsequent Phase 3 STAR readout (June 2021) failed primary and secondary endpoints, and Biogen exited the program.